Molecular Templates, Inc. (MTEM) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Molecular Templates, Inc. (MTEM) Healthcare & Pipeline Overview

Molecular Templates, Inc. is a clinical-stage biotechnology firm leveraging its proprietary biologic engineered toxin body (ETB) platform to develop novel therapeutics for cancer and serious diseases. With multiple candidates in Phase I trials and a strategic collaboration, the company focuses on advancing targeted oncology treatments within the competitive biopharmaceutical landscape.

What Is the Investment Thesis for MTEM?

Molecular Templates, Inc. presents an investment thesis centered on its proprietary biologic engineered toxin body (ETB) platform, which offers a differentiated approach to targeted cancer therapy. The company's pipeline, featuring MT-5111 for HER2-positive cancers, MT-0169 for relapsed/refractory myeloma, and MT-6402 for PD-1/PD-L1 refractory patients, all in Phase I clinical trials, represents potential future value drivers. The ongoing collaboration with Bristol Myers Squibb provides a strategic partnership, offering external validation of the ETB technology and potential for shared development resources and future commercialization. While the company operates with a negative profit margin of -14.2% and a market capitalization of $0.00B, typical for a clinical-stage biotechnology firm, successful advancement of its ETB candidates through later-stage clinical trials and regulatory approval could significantly unlock value. The high gross margin of 87.9% suggests strong potential profitability if products reach market. The company's beta of 1.53 indicates higher volatility relative to the market, characteristic of the biotechnology sector.

Based on FMP financials and quantitative analysis

MTEM Key Highlights

Molecular Templates, Inc. operates as a clinical-stage biopharmaceutical company, with its primary focus on research and development of its proprietary ETB platform.

• The company maintains a strong gross margin of 87.9%, indicating efficient cost management relative to its revenue, despite being pre-commercial.
• Molecular Templates, Inc. reported a profit margin of -14.2%, which is typical for a biotechnology company in the clinical development phase with significant R&D expenses.
• The company has a market capitalization of $0.00B, reflecting its early stage of development and the inherent risks associated with clinical trials.
• A beta of 1.53 suggests that the company's stock price tends to be more volatile than the broader market, consistent with the biotechnology industry's risk profile.

Who Are MTEM's Competitors?

MTEM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MTEM's Key Strengths?

Proprietary Biologic Engineered Toxin Body (ETB) platform offers a novel approach to targeted cancer therapy.

• Strategic collaboration with Bristol Myers Squibb provides validation, resources, and potential future revenue streams.
• Diverse pipeline of ETB candidates targeting multiple indications, including HER2-positive cancers and various refractory conditions.
• High gross margin of 87.9% indicates strong potential profitability if products reach commercialization.

What Are MTEM's Weaknesses?

Clinical-stage company with no commercialized products, leading to a negative profit margin of -14.2% and reliance on funding.

• Small market capitalization of $0.00B, indicative of early-stage development and potential for high volatility.
• All lead candidates are in Phase I clinical trials, representing significant development risk and long timelines to market.
• Trades on the OTC market, which may limit liquidity and investor access compared to major exchanges.

What Could Drive MTEM Stock Higher?

MTEM catalyst: Positive data readouts from ongoing Phase I clinical trials for MT-5111 (HER2-positive cancers), MT-0169 (relapsed/refractory myeloma), and MT-6402 (PD-1/PD-L1 antibody relapsed/refractory patients).

• Advancement of any lead ETB candidates from Phase I to Phase II clinical trials, signaling progress in development.
• Further development milestones or expanded scope within the collaboration agreement with Bristol Myers Squibb, potentially including new targets or increased funding.
• Announcement of new preclinical data or initiation of new ETB programs targeting additional indications (e.g., CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, CD45).

What Are the Key Risks for MTEM?

Financial-distress signal — its Altman Z-Score of -24.91 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of any of the company's lead ETB candidates (MT-5111, MT-0169, MT-6402) in clinical trials due to lack of efficacy or unacceptable safety profiles.
• Significant capital requirements and potential for future dilution through equity financing to fund extensive research and development activities.
• Intense competition from other pharmaceutical and biotechnology companies developing therapies for cancer and serious diseases, including those with more advanced pipelines.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities for clinical trials and eventual market authorization.
• Dependence on the success of its proprietary ETB platform; a fundamental flaw or limitation in the technology could severely impact the company's viability.

What Are the Growth Opportunities for MTEM?

• Advancement of MT-5111 for HER2-positive cancers: The successful progression of MT-5111 through Phase I and into later-stage clinical trials represents a significant growth opportunity. HER2-positive cancers, including breast and gastric cancers, affect a substantial patient population, and while existing treatments are available, there remains a need for novel therapies, especially for resistant cases. Demonstrating efficacy and safety in further trials could position MT-5111 as a valuable addition to the treatment landscape, potentially leading to substantial market penetration upon approval. The current market size for HER2-targeted therapies is significant, and a differentiated ETB approach could capture a meaningful share.
• Progression of MT-0169 for relapsed/refractory myeloma: Multiple myeloma, particularly in its relapsed or refractory forms, presents a challenging clinical scenario with limited effective long-term treatment options. The advancement of MT-0169 through clinical development offers a critical growth pathway. Positive data from Phase I and subsequent trials could establish MT-0169 as a new therapeutic option for patients who have exhausted other treatments. The market for multiple myeloma therapies is robust and growing, driven by an aging population and increasing incidence, making a successful drug in this area a strong value driver for Molecular Templates, Inc.
• Development of MT-6402 for PD-1/PD-L1 antibody relapsed/refractory patients: Patients who become resistant to PD-1/PD-L1 checkpoint inhibitors represent a significant unmet medical need in oncology. MT-6402, targeting this population, has the potential to address a critical gap in cancer treatment. Successful clinical development and eventual approval of MT-6402 could open access to a patient segment that currently has few effective alternatives. The market for immunotherapies is one of the largest and fastest-growing in oncology, and a therapy that can overcome resistance mechanisms would command a premium and substantial market share.
• Expansion of the ETB platform to new targets: Molecular Templates, Inc.'s ongoing research into additional targets such as CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45 provides a broad pipeline expansion opportunity. Each of these targets is implicated in various cancers and serious diseases, representing distinct potential therapeutic avenues. Successful preclinical and early clinical development for any of these new ETB candidates could significantly diversify the company's pipeline, reduce reliance on lead programs, and open up entirely new market segments, thereby enhancing long-term growth prospects and intellectual property portfolio.
• Leveraging the Bristol Myers Squibb collaboration: The strategic collaboration with Bristol Myers Squibb is a significant growth catalyst. This partnership not only provides external validation of Molecular Templates' ETB platform but also offers access to additional resources, expertise, and potential funding for drug discovery and development. Successful outcomes from this collaboration, such as the identification of novel ETB products or the advancement of partnered candidates into later clinical stages, could lead to milestone payments, royalties, and shared commercialization opportunities, substantially accelerating Molecular Templates' growth and market presence without solely relying on its internal capital.

What Threats Does MTEM Face?

• High risk of clinical trial failures, which could lead to significant delays, increased costs, or termination of programs.
• Intense competition from established pharmaceutical companies and other biotechnology firms developing oncology treatments.
• Regulatory hurdles and lengthy approval processes inherent in the biopharmaceutical industry.
• Need for substantial additional funding to complete clinical development, potentially leading to dilution for existing shareholders.
• Market volatility and investor sentiment shifts, particularly for clinical-stage companies on the OTC market.

What Are MTEM's Competitive Advantages?

• Proprietary Biologic Engineered Toxin Body (ETB) platform, representing a unique drug delivery and mechanism of action.
• Extensive intellectual property surrounding the ETB technology and specific drug candidates, providing patent protection.
• Strategic collaboration with a major pharmaceutical company, Bristol Myers Squibb, validating the technology and providing resources.
• Specialized focus on challenging cancer targets and patient populations with unmet medical needs, allowing for focused expertise.
• First-mover advantage or unique efficacy profiles if ETB candidates demonstrate superior outcomes in clinical trials.

What Does MTEM Do?

Molecular Templates, Inc., founded in 2001 and headquartered in Austin, Texas, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative biologic therapeutics. The company's core focus is on addressing cancer and other serious diseases through its proprietary biologic engineered toxin body (ETB) drug platform. This platform represents a distinct approach to targeted therapy, aiming to deliver potent cytotoxic agents directly to cancer cells while minimizing systemic toxicity. The ETB platform is central to Molecular Templates' strategy, underpinning its entire pipeline of investigational therapies. The company's development pipeline includes several promising ETB candidates currently in Phase I clinical trials. MT-5111 is being evaluated for the treatment of HER2-positive cancers, a significant area of unmet medical need. Another key candidate, MT-0169, is progressing through Phase I for relapsed/refractory myeloma patients, targeting a challenging blood cancer. Additionally, MT-6402 is in Phase I clinical trials for patients with PD-1/PD-L1 antibody relapsed/refractory disease, addressing resistance mechanisms in immunotherapy. Beyond these lead programs, Molecular Templates, Inc. is actively developing a broader pipeline of ETBs designed to target various other critical markers, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45, indicating a robust and diversified research effort. Further bolstering its development capabilities and market potential, Molecular Templates, Inc. has established a significant collaboration agreement with Bristol Myers Squibb. This partnership is focused on discovering and developing novel products that incorporate ETBs directed to multiple targets, providing external validation of the ETB platform and potentially accelerating the advancement of new therapeutic options. As a clinical-stage entity, the company's operations are heavily centered on research and development, with a strategic emphasis on progressing its pipeline through various clinical phases towards potential commercialization.

What Products and Services Does MTEM Offer?

• Develops biologic therapeutics for cancer and other serious diseases.
• Utilizes a proprietary biologic engineered toxin body (ETB) drug platform.
• Conducts Phase I clinical trials for MT-5111, targeting HER2-positive cancers.
• Conducts Phase I clinical trials for MT-0169, for relapsed/refractory myeloma patients.
• Conducts Phase I clinical trials for MT-6402, for PD-1/PD-L1 antibody relapsed/refractory patients.
• Explores additional ETB candidates for targets like CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45.
• Collaborates with Bristol Myers Squibb to discover and develop novel ETB products.
• Focuses on research and development as a clinical-stage biopharmaceutical company.

How Does MTEM Make Money?

• Primarily generates revenue through collaboration agreements, such as the one with Bristol Myers Squibb, which may include upfront payments, milestone payments, and potential royalties on future sales.
• Invests heavily in research and development to advance its proprietary ETB drug candidates through preclinical and clinical trial phases.
• Aims to commercialize its own ETB therapeutics upon successful regulatory approval, generating revenue from direct product sales.
• Potentially seeks additional partnerships or licensing agreements for its ETB platform or specific drug candidates to fund development and expand market reach.
• Operates as a clinical-stage company, meaning current revenue streams are limited, with significant future revenue contingent on successful drug development and market entry.

What Industry Does MTEM Operate In?

Molecular Templates, Inc. operates within the highly innovative and competitive biotechnology industry, specifically focusing on oncology and serious diseases. This sector is characterized by extensive research and development efforts, long development timelines, and significant regulatory hurdles. The broader market trend is towards targeted therapies and immunotherapies, where Molecular Templates' proprietary biologic engineered toxin body (ETB) platform aims to offer a novel mechanism of action. The competitive landscape includes numerous pharmaceutical giants and smaller biotech firms developing cancer treatments, making differentiation crucial. As a clinical-stage company, Molecular Templates is positioned in the high-risk, high-reward segment of the industry, where success in clinical trials can lead to substantial market opportunities, while failures can significantly impact viability. The company's focus on specific targets like HER2, myeloma, and PD-1/PD-L1 refractory patients places it in direct competition with established and emerging therapies in these areas.

Who Are MTEM's Key Customers?

• Future patients suffering from HER2-positive cancers, relapsed/refractory myeloma, and PD-1/PD-L1 antibody relapsed/refractory diseases, upon successful drug approval.
• Pharmaceutical companies seeking innovative drug candidates and platform technologies for collaboration, such as Bristol Myers Squibb.
• Oncology specialists and healthcare providers who would prescribe or administer approved ETB therapies.
• Hospitals and healthcare systems that would purchase and utilize the company's therapeutic products.

Molecular Templates, Inc. (MTEM) Valuation Context

Relative to its peer group, MTEM's quantitative score of 68/100 is roughly in line with the peer average of 76/100.

MTEM Revenue & Earnings Trend

In Q2 2024, MTEM generated $572K in top-line revenue, marking a sequential decrease of 94.8%. The company recorded a net loss of $8.1M, with diluted EPS of $-1.23.

Company Profile

Molecular Templates, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Eric E. Poma. MTEM has traded publicly since 2005.

Return on equity for Molecular Templates, Inc. stands at 148.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.0%, showing how much profit it generates from its asset base. A current ratio of 0.97 means current liabilities exceed short-term assets, a liquidity point worth watching.

Molecular Templates, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.91 places it in the distress zone, a signal of elevated financial risk.

Molecular Templates, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 6.1% above estimates on average.

Wall Street analysts project Molecular Templates, Inc. revenue of about $26.7M for fiscal 2026, with EPS near $-40.95.

MTEM Financials

MTEM Latest News

No recent news available for MTEM.

MTEM Analyst Consensus

MTEM MoonshotScore

What Investors Ask About Molecular Templates, Inc. (MTEM) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources